

List of Tables

Table 1: Symptoms of type 1 and type 2 diabetes mellitus.....	3
Table 2: Currently available anti-diabetic drugs ^{104, 107}	13
Table 3: Available anti-obesity drugs.	15
Table 4: Endogenous ligands for GPR-119 agonist. ¹³⁵	23
Table 5: Some GPR-119 agonists under clinical trials ¹³⁵	27
Table 6: GPR119 agonistic activities of compounds 16a-e, g, k, l and 17 a-l.....	40
Table 7: Pharmacokinetic parameters ^a in fasted SD Rats at 25 mg/kg dose.....	42
Table 8: The oGTT effect ^a of compounds 16c, 17c & 16l in C57 and db/db mice.....	43
Table 9: GPR119 agonistic activities of compounds 23 a-n and 24 a-m.....	47
Table 10: Pharmacokinetic Parameters ^a of compounds 23c, 23i and 23l.	49
Table 11: The oGTT effect a of compounds 23c in C57 and db/db mice.....	50
Table 12: Glide score and binding energies of compound 23c.	51
Table 13: GPR119 agonistic activities of compounds 25 a-k.....	52
Table 14: Primary Biochemical Assay results at 10 μ M concentration.	54
Table 15: in-vitro metabolic stability of compound 23c.....	56
Table 16: Pharmacokinetic parameters ^a of compound 23c in male species.	56
Table 17: Pharmacokinetic parameters ^a of compound 23c in Female species.....	57
Table 18: Tissue distribution ^a of compound 23c in Wistar rats.....	57
Table 19: Distribution of compound 23c in whole blood.....	58
Table 20: Preliminary toxicity study of compound 23c.	63
Table 21: Biochemical Parameters of the compound 23c in Wistar rats for 28 days.....	64
Table 22: Histopathological Findings of compound 23c in Wistar rats for 28 days.....	65
Table 23: Relative organ weights ^a of Wistar rats administered orally with compound 23c for 28 days.....	66
Table 24: Haematological Estimations of Wistar rats administered orally with compound 23c for 28 days.....	67